The UK has the potential to become a global leader in the AssitiveTech Industry. Our report showcases the importance of AssistiveTech in driving social inclusion and highlights the UK’s efforts in providing support for those in need of using advanced technologies.
Join us in the House of Lords to take a first-hand look at a comprehensive review of the UK’s assistive technology landscape overview. This newly created report focuses on industry participants, its major trends and obstacles and the support of the UK Government towards the assistive tech Industries.
Biomarkers of Human Longevity: State of the Market and Diversity of Practical Applications Q4 2021 is an upcoming 2-day virtual conference featuring talks and panel discussions among industry leaders, companies, investors and practitioners in the rapidly growing domain of Biomarkers of Human Longevity.
The event is free-of-charge to attend, and will provide a stat-of-the-market overview and key company and investor take-aways for Q4 2021, highlighting key industry trends, challenges, opportunities and recent developments, and explore the rapidly growing diversity of market-ready, practical applications within the industry.
“Longevity.International presents: Biomarkers Of Human Longevity” was a virtual 1-day conference that took place June 30, 2021 featuring presentations from a variety of companies, key players and thought-leaders active within the Biomarkers of Human Aging and Longevity Industry.
The event explored the present state of the industry, as well as key strategic challenges and opportunities for translating the potentials of Biomarkers of Human Longevity from theory into practice.
"Practical Applications of Mitochondria Research for Human Longevity and Space Medicine" was a virtual conference that took place June 9-10, 2021, where professionals from Aging Analytics Agency and guest speakers who are Practical Longevity Experts, Space Medicine Experts and Women Influencers shared insights, findings and personal experiences about the Role of Mitochondria in The Practical Human Longevity and Scientific Approaches to Women For Extending Reproductive Longevity.
Episode 1 of the new series Practical Human Longevity focused on market-ready technologies and approaches for Intermittent Hypoxia, Hyperoxia and their relation to Mitochondrial Aging and Healthy Human Longevity. Kaminskiy and Prokopov considered the pros and cons of different approaches within this general paradigm during their discussion. They showcased the tangible results on health and performance that Kaminskiy has experienced since beginning to integrate these technologies into his daily Personal Longevity Regime, followed by a keynote lecture on the tangible links between intermittent hypoxia and hyperoxia and human aging and Longevity.
The world’s first international, cross-border, cross-sector summit on International Longevity Policy and Governance as part of Longevity Forum’s Longevity Week 2019, bringing together world-leading policy experts, representatives of government bodies, departments, healthcare and finance ministries, executives of healthcare and financial corporations to discuss, network and collaborate on initiatives to promote international longevity development.
The inaugural, exclusive and invitation-only AI for Longevity Summit, organized at King’s College London, brought together leading scientists, industry players, and experts to highlight the latest advances in Artificial Intelligence for Longevity and the practical implementation of longevity technologies and therapeutics. It was the first in a series of conferences, which we expect to become the world-leading forum on AI for Longevity.
Targeting Metabesity 2019 conference focused on the prevention of noncommunicable diseases and the treatment of age-related health dysfunctions to extend health-adjusted life expectancy. The conference, was held October 15-16, 2019 at the Carnegie Institution for Science in Washington, D.C., addressed one of the important issues in healthcare: the constellation of major chronic diseases, including diabetes, cardiovascular disease, dementia, cancer, and the aging process, that are considered to be the “slow motion disaster”.